ProCE Banner Activity

NeoTrio: Neoadjuvant Pembrolizumab Alone, Combined With, or in Sequence With Dabrafenib and Trametinib in Resectable BRAFV600-Mutant Stage III Melanoma

Slideset Download
Conference Coverage
Concurrent neoadjuvant dabrafenib and trametinib and pembrolizumab resulted in high pathologic response rate in patients with stage III melanoma, although with increased toxicity compared with sequential regimen or pembrolizumab monotherapy.

Released: June 09, 2022

Expiration: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab